

BMC Non-urine

System Non-urine

System Urine

SMC Non-urine

BMC Urine

SMC Urine

Integris Southwest Medical Center 2024 Urine Antibigram Report

Cumulative Report: January-December 2024

| SUSCEPTIBILITY PERCENTAGE (%) Percentages do not include intermediate calls. | | | | | | | | | | | | | | | | | | | | |
|--|---------------------------------|--------------------|--|------------|----------------------|----------|-------------|-------------|---------------|------------|-----------|-----------|----------------|-----------------------|------------|-------------------------|----------------------------|------------|---------------|------------|
| | Organism | Number of Isolates | Amikacin | Ampicillin | Ampicillin/Sulbactam | Cefepime | Ceftazidime | Ceftriaxone | Ciprofloxacin | Gentamicin | Linezolid | Meropenem | Nitrofurantoin | Oxacillin (Nafcillin) | Penicillin | Piperacillin/Tazobactam | Tetracycline (Doxycycline) | Tobramycin | Trimeth/Sulfa | Vancomycin |
| GRAM POSITIVE | Staphylococcus epidermidis | 19 | | | | | | | | | | | 100 | 53 | 11 | | 84 | | 58 | 100 |
| | Enterococcus faecalis** | 101 | | 100 | | | | | 75 | | 100 | | 100 | | 99 | | | | | 94 |
| | Enterococcus faecium** | 32 | | 3 | | | | | 3 | | 100 | | 38 | | 3 | | | | | 31 |
| | Staphylococcus aureus* | 21 | | | | | | | | | | | 100 | 57 | 10 | | 95 | | 95 | 100 |
| GRAM NEGATIVE | Acinetobacter baumannii complex | 1 | | | 100 | 100 | 100 | 0 | 100 | 100 | | 100 | | | | 100 | | 100 | 100 | |
| | Citrobacter freundii complex | 17 | | | | 100 | 65 | 65 | 94 | 94 | | 100 | | | | 71 | | 100 | 94 | |
| | Citrobacter koseri | 8 | | | | 100 | 100 | 100 | 100 | 100 | | 100 | 75 | | | 100 | | 100 | 100 | |
| | Enterobacter aerogenes | 30 | | | | 100 | 87 | 87 | 97 | 97 | | 100 | 10 | | | 87 | | 97 | 100 | |
| | Enterobacter cloacae complex | 35 | | | | 97 | 94 | 74 | 86 | 100 | | 100 | 50 | | | 58 | | 100 | 85 | |
| | Escherichia coli | 1,073 | | 46 | 61 | 96 | 94 | 86 | 71 | 88 | | 100 | 96 | | | 96 | | 89 | 70 | |
| | Klebsiella oxytoca | 16 | | | 50 | 100 | 100 | 94 | 100 | 100 | | 100 | 69 | | | 81 | | 100 | 94 | |
| | Klebsiella pneumoniae | 239 | | | 72 | 90 | 87 | 79 | 75 | 91 | | 99 | 23 | | | 91 | | 89 | 79 | |
| | Morganella morganii | 12 | | | 17 | 100 | 83 | 92 | 75 | 83 | | 100 | | | | 100 | | 100 | 83 | |
| | Proteus mirabilis | 105 | | 73 | 89 | 95 | 99 | 93 | 79 | 88 | | 98 | | | | 99 | | 91 | 79 | |
| | Pseudomonas aeruginosa | 41 | 98 | | | 83 | 85 | | 85 | 95 | | 93 | | | | | 83 | | 98 | |
| Blank = Not Tested or Not Clinically Indicated | | | Yellow shaded areas represent an eighty-five percent (85%) or greater susceptible drug | | | | | | | | | | | | | | | | | |

Organisms listed qualify as statistically significant. Statistically significant if defined as organisms with more than thirty (30) isolates per the Clinical Laboratory Standards Institute (Document M39-ED5-2022).

* 43% (9 of 21) of Staph aureus isolates were MRSA

** 69% (22 of 32) of E. faecium isolates & 5.9% (6 of 101) E. faecalis isolates were Vancomycin resistant

14% (150 of 1073) of E. coli isolates, 6.7% (7 of 105) P. mirabilis, & 21% (50 of 239) of K. pneumo isolates produced extended spectrum beta-lactamases (ESBL)

0% (0 of 1073) of E. coli, 1.3% (3 of 239) K. pneumo isolates, & 7.3% (3 of 41) P. aeruginosa isolates were identified as carbapenem-resistant